A Trial to Demonstrate Bioequivalence Between Semaglutide Formulations for the DV3372 Device and the Formulation for the PDS290 Semaglutide Pen-injector
Phase of Trial: Phase I
Latest Information Update: 01 Feb 2019
Price : $35 *
At a glance
- Drugs Semaglutide (Primary)
- Indications Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis; Obesity; Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Novo Nordisk
- 01 Feb 2019 Last checked against ClinicalTrials.gov record.
- 24 Jan 2019 Status changed from active, no longer recruiting to completed.
- 23 Oct 2018 Status changed from recruiting to active, no longer recruiting.